greeksoup/ stock research
Stock research / United States / Funds / Checkpoint Capital L.P.

Checkpoint Capital L.P.

CIK 1977548 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Checkpoint Capital L.P. reported 6 US-listed holdings worth $389.8 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Rhythm Pharmaceuticals Inc. (33.8%), argenx SE (31.3%) and Revolution Medicines, Inc. (19.7%). Against the quarter before, it opened 0 positions, added to 3, trimmed 3 and sold out of 2.

Reported holdings$389.8M+39.9% on Q1 2026
Positions6-2 on Q1 2026
The largest ten100.0%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
Added toTrimmed
RYTM33.8%ARGX31.3%RVMD19.7%CYTK10.4%IRON4.5%

The 6 largest of its 6 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $201.6 million in 16 positions$202MQ3 24Q4 2024: $196.5 million in 16 positions$196MQ4 24Q1 2025: $182.3 million in 14 positions$182MQ1 25Q2 2025: $214.6 million in 8 positions$215MQ2 25Q3 2025: $298.5 million in 10 positions$298MQ3 25Q4 2025: $315.6 million in 6 positions$316MQ4 25Q1 2026: $278.7 million in 8 positions$279MQ1 26Q2 2026: $389.8 million in 6 positions$390MQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What its reported holdings returned

Held through each quarter, the holdings it reported returned +76.7% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.

Its reported holdingsThe S&P 500
90120150180Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Its holdings +76.7%S&P 500 +30.2%

Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.

What it did on the quarter

Added 3Trimmed 3Sold out 2
Added: 3Trimmed: 3Sold out: 2

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Added to 3

  1. Revolution Medicines, Inc. RVMD+147,814 shares · +56%
  2. Cytokinetics Inc. CYTK+295,000 shares · +164%
  3. Trevi Therapeutics Inc. TRVI+25,000 shares · +50%

Trimmed 3

  1. argenx SE ARGX-21,717 shares · -14%
  2. Rhythm Pharmaceuticals Inc. RYTM-41,200 shares · -3%
  3. Disc Medicine Inc. IRON-46,536 shares · -16%

Sold out of 2

  1. Septerna Inc. SEPN$2.4 million last quarter
  2. Crinetics Pharmaceuticals in CRNX$1.5 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Rhythm Pharmaceuticals Inc. RYTM1.2M$131.7 million33.79%-41.2K
argenx SE ARGX131.3K$121.8 million31.25%-21.7K
Revolution Medicines, Inc. RVMD410.4K$76.9 million19.72%+147.8K
Cytokinetics Inc. CYTK475.0K$40.5 million10.38%+295.0K
Disc Medicine Inc. IRON240.1K$17.6 million4.51%-46.5K
Trevi Therapeutics Inc. TRVI75.0K$1.4 million0.36%+25.0K
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 2 it sold out of are in the box above.